Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04601233 · ClinicalTrials.gov registry record · Phase 4
Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis
A Phase 4 study, sponsored by Tulane University.
- Not yet
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT04601233 is a Phase 4 study that has not yet begun recruiting, run by Tulane University. The registered enrollment target is 20 participants.
The verdict
NCT04601233, a Phase 4 study, has not yet begun recruiting, sponsored by Tulane University.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the effects of testosterone treatment on erectile function, fatigue, depression, cognitive function, quality of life, urinary incontinence, pain, and damage to neurons in male Multiple Sclerosis patients with low testosterone, using questionnaires, blood samples and a rectal exam in volunteers 55 years and older.
Interventions
- DRUG XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-06 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04601233
The ClinicalTrials.gov registry entry for NCT04601233 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tulane University, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector is the first listed.
NCT04601233 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04601233 about?
NCT04601233 is a clinical study titled "Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis". The purpose of the study is to determine the effects of testosterone treatment on erectile function, fatigue, depression, cognitive function, quality of life, urinary incontinence, pain, and damage to neurons in male Multiple Sclerosis patients with low testosterone, using questionnaires, blood samp...
What is the current status of trial NCT04601233?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2026-06. Estimated completion is 2026-12.
What interventions are being tested in trial NCT04601233?
The interventions under investigation include: XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector (DRUG).
Who is sponsoring clinical trial NCT04601233?
This trial is sponsored by Tulane University, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.